Myriad Genetics stock fell 8.51 percent to USD 3.98 on October 16, 2026

Published on 10/17/2026 at 20:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results come November 4, 2026. Myriad Genetics stock fell to USD 3.98 on October 16, 2026, down 8.51 percent versus the Nasdaq close of USD 4.35.

Dates and market levels

Myriad Genetics will publish third-quarter results on November 4, 2026.
Second-quarter revenue was USD 190.70 million, down 10.50 percent year over year.
Myriad Genetics stock stood at USD 3.98 at 4:00 p.m. EDT on October 16, 2026, down 8.51 percent versus the Nasdaq close of October 15, 2026.
Market capitalization stood at USD 380.7 million on October 16, 2026.

MYGN, US62855J1043, Illustration mit AI erstellt.

Myriad Genetics will release its third-quarter 2026 results on November 4, 2026, after the market closes and will hold its earnings call at 4:30 p.m. ET, according to Yahoo Finance. The Nasdaq closing price was USD 3.98 at 4:00 p.m. EDT on October 16, 2026, down 8.51 percent versus the Nasdaq close of October 15, 2026 at USD 4.35.

Revenue remains the operating test

Myriad Genetics reported second-quarter 2026 revenue of USD 190.70 million, down 10.50 percent from USD 213.10 million in the same quarter of 2025. The company also reported a net loss of USD 43.20 million, compared with a USD 330.50 million loss in the year-ago quarter, according to MarketBeat. The revenue decline keeps the November report central to the stock's next valuation reset.

Stock remains below its yearly high

The October 16 session ranged from USD 3.97 to USD 4.31, with 1,139,244 shares traded against an average volume of 2,086,850 shares. The 52-week range was USD 2.74 to USD 8.50, putting the closing price 53.18 percent below the high. Myriad Genetics was down 35.28 percent year to date through October 16, 2026.

Valuation and the next report

Market capitalization stood at USD 380.7 million on October 16, 2026. The price-to-earnings ratio was negative 3.33 and the dividend yield was zero. The November 4, 2026 results release is the next dated company event and will provide the next comparison with the second-quarter revenue base.

Comparison with peers

Myriad Genetics (Nasdaq, USD): minus 8.51 percent, price-to-earnings ratio minus 3.33, market capitalization USD 380.7 million.
Illumina (Nasdaq, USD): minus 2.01 percent, price-to-earnings ratio 48.98, market capitalization USD 39.6 billion.
Natera (Nasdaq, USD): minus 2.80 percent, price-to-earnings ratio minus 289.29, market capitalization USD 56.7 billion.

The Nasdaq close sets the line

Myriad Genetics closed at USD 3.98 on October 16, 2026, with the session's low at USD 3.97 and high at USD 4.31. The next scheduled checkpoint is the third-quarter report on November 4, 2026.